Basilea pharma - Isavuconazole SECUREs Primary endpoint – Watch out for ACTIVE and VITAL!
Basilea pharma (BSLN) along with its partner, Astellas is co-developing antifungal Isavuconazole (PhIII) for invasive fungal infections. Isavuconazole demonstrated non-inferiority vs. voriconazole in its international PhIII, SECURE trial in pts (n = 516) with invasive fungal disease caused by Aspergillus species or certain other filamentous fungi. Both intravenous (IV) and oral formulation of Isavuconazole offer flexible dosing options, in addition to a broad spectrum of activity and thus, it may offer potential benefits over the current gold standard (Vfend, Cancidas). With an increasing rate of serious infections and resistance to current drugs, we. For more detail, please read our report, released on 30th Sept., 2013 on BSLN, titled, 'Isavuconazole SECUREs Primary endpoint – Watch out for ACTIVE and VITAL! '
More Publications
Bayer, Pfizer, Bristol Myers Squibb - Xarelto meets primary endpoint of ATLAS TIMI ACS- Strengthening its position in anticoagulant space
US$ 140.00
September 2011
8 pages
MERCK - Vorapaxar: Subgroup Analyses Hold the Key: TRA-2P study Met Primary Endpoint
US$ 90.00
February 2012
2 pages
Lemtrada: Co-primary Endpoints Met in CARE MS II: Ready for filing
US$ 90.00
November 2011
4 pages
